telitacicept
Sponsor Vor Biopharma INC. · listed as VOR
telitacicept is a drug asset sponsored by Vor Biopharma INC., listed as VOR. CSA tracks 1 forward catalyst for it — the nearest is a readout expected May 2027 (month precision, medium confidence), tied to trial NCT06456580. That trial is in Phase 3 and currently recruiting, studying Generalized Myasthenia Gravis. It appears across 2 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
Trials for telitacicept in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT07249632 | Phase 3 | Recruiting | 2026-12-31 | Experimental | RemeGen Co., Ltd. | Myasthenia Gravis, Ocular |
| NCT06456580 catalyst | Phase 3 | Recruiting | 2027-05 | Experimental | Vor Biopharma | Generalized Myasthenia Gravis |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More VOR catalysts